A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
NCT04225156
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
101
Enrollment
INDUSTRY
Sponsor class
Conditions
Primary Immune Thrombocytopenia
Interventions
BIOLOGICAL:
efgartigimod
Sponsor
argenx